Intellia Therapeutics Inc.

History

Year	Detail
2014	Intellia Therapeutics Inc. was established to serve people with severe diseases by developing curative genome editing treatments.
2015	Intellia collaborated with Novartis to develop novel cell therapies by utilizing Intellia’s ex-vivo CRISPR/Cas9 platform.
2016	Intellia introduced a proprietary lipid nanoparticle (LNP) delivery system in preclinical studies, driving the precise delivery of CRISPR/Cas9 to target cells.
2018	The company unveiled editing of the TTR gene in liver cells of non-human primates with therapeutically relevant reduction of serum TTR protein.
2021	Intellia showcased systemic in vivo genome editing in tissue outside the liver in preclinical models, with the potential to treat sickle cell disease and other inherited blood disorders less invasively.
2023	Intellia received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for NTLA-2002, which is for the treatment of hereditary angioedema (HAE).